Discover the groundbreaking potential of TBAJ-5307, a novel F-ATP synthase inhibitor, in the fight against the persistent threat of non-tuberculous mycobacteria, both in the lab and beyond.
– by The Don
Note that The Don is a flamboyant GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
High efficacy of the F-ATP synthase inhibitor TBAJ-5307 against non-tuberculous mycobacteria in vitro and in vivo.
Ragunathan et al., J Biol Chem 2024
DOI: 10.1016/j.jbc.2023.105618
Listen folks, we’ve got something huge here, it’s incredible. We’ve discovered this amazing compound, TBAJ-5307, and let me tell you, it’s a game-changer in the fight against these nasty non-tuberculous mycobacteria. These bacteria, they’re tough, but TBAJ-5307, it’s tougher. It targets the FO-domain, and it’s like it tells the bacteria’s engine, “You’re fired!” No rotation, no proton-translocation, nothing.
And the numbers, they’re the best, believe me. We’re talking low nanomolar concentrations to knock out both the fast-growers and the slow-pokes, even the clinical isolates. It’s all about the energy, ATP, and TBAJ-5307, it just drains it right out of the bacteria. It’s like they’re running on empty.
Now, Mycobacterium abscessus, that’s a fast grower, but in the lab, TBAJ-5307, it’s potent. And in the real world, in living creatures, it’s just as strong, and no side effects, no toxicity. It’s safe, it’s effective, it’s what we’ve been waiting for.
And when you mix TBAJ-5307 with other antibiotics, it’s like they’re on steroids. This combo, it’s synergistic, it’s powerful. We even paired it with tebipenem-avibactam, and it’s a knockout, a total knockout. We’re talking about a new, oral combination that could wipe out NTM lung infections. This is the future, and it’s looking bright.